ConductScience.org, home

Paper41277909

Chemotherapy response monitoring with DNA methylation-based ctDNA tumor fraction: Evidence from a real-world cohort of patients with advanced common solid malignancies.

Rolfo CD and 11 others. J Liq Biopsy, 2025. Cited by 6 papers, by iCite.

Cite this record

ConductScience Library. Chemotherapy response monitoring with DNA methylation-based ctDNA tumor fraction: Evidence from a real-world cohort of patients with advanced common solid malignancies. Papers, record 41277909. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41277909

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Chemotherapy response monitoring with DNA methylation-based ctDNA tumor fraction: Evidence from a real-world cohort of patients with advanced common solid malignancies.
PubMed
Journal
J Liq Biopsy
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
1.33, provisional
iCite
Revised in PubMed
2026-01-09
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rolfo CDChristian D
2Khushman MMMoh'd M
3Russo AAlessandro
4Borea RRoberto
5Herrman BBernard
6Wang JJing
7Liao JJiemin
8Espenschied CRCarin R
9Gordon SSean
10Quinn KKatie
11Banks KCKimberly C
12Medford AJArielle J

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum in41509815
Corrigendum to "Chemotherapy response monitoring with DNA methylation-based ctDNA tumor fraction: Evidence from a real-world cohort of patients with advanced common solid malignancies" [J Liq Biopsy, 10 (2025), 100442].
https://conductscience.org/library/papers/41509815

Source PubMed

Download CSV of comments and corrections

References48

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137702716Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer.Clin Cancer Res2023https://conductscience.org/library/papers/37702716PubMed
231335166An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer.JCO Clin Cancer Inform2019https://conductscience.org/library/papers/31335166PubMed
335779872An overview of chemotoxicity and radiation toxicity in cancer therapy.Adv Cancer Res2022https://conductscience.org/library/papers/35779872PubMed
439352380Distinct landscape and clinical implications of therapy-related clonal hematopoiesis.J Clin Invest2024https://conductscience.org/library/papers/39352380PubMed
536869646Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients.Cancer2023https://conductscience.org/library/papers/36869646PubMed
629330207Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.Clin Cancer Res2018https://conductscience.org/library/papers/29330207PubMed
735008291Prediction of Chemotoxicity, Unplanned Hospitalizations and Early Death in Older Patients with Colorectal Cancer Treated with Chemotherapy.Cancers (Basel)2021https://conductscience.org/library/papers/35008291PubMed
831941831Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers.Clin Cancer Res2020https://conductscience.org/library/papers/31941831PubMed
930541742Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.Cancer Res2019https://conductscience.org/library/papers/30541742PubMed
1039037536Dynamic Changes in Circulating Tumor Fraction as a Predictor of Real-World Clinical Outcomes in Solid Tumor Malignancy Patients Treated with Immunotherapy.Oncol Ther2024https://conductscience.org/library/papers/39037536PubMed
1140728234Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study.Cancer Res Commun2025https://conductscience.org/library/papers/40728234PubMed
1236265119Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples.JCO Precis Oncol2022https://conductscience.org/library/papers/36265119PubMed
1332816849Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade.Cancer Discov2020https://conductscience.org/library/papers/32816849PubMed
1433411622Comparisons of Real-World Time-to-Event End Points in Oncology Research.JCO Clin Cancer Inform2021https://conductscience.org/library/papers/33411622PubMed
1535308944Validation of Real-World Data-based Endpoint Measures of Cancer Treatment Outcomes.AMIA Annu Symp Proc2021https://conductscience.org/library/papers/35308944PubMed
1630368012Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer.J Thorac Oncol2019https://conductscience.org/library/papers/30368012PubMed
1736208697Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study.Ann Oncol2023https://conductscience.org/library/papers/36208697PubMed
1837789101Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors.Br J Cancer2023https://conductscience.org/library/papers/37789101PubMed
1936928816A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer.Nat Med2023https://conductscience.org/library/papers/36928816PubMed
2037814061ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.Nat Med2023https://conductscience.org/library/papers/37814061PubMed

See all 48 referencesDownload CSV of references

Cited by9

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
42886888Plasma-Derived Genomic Instability Status and Rucaparib Outcomes in Metastatic Castration-Resistant Prostate Cancer: TRITON2.JCO Precis Oncol2026https://conductscience.org/library/papers/42886888PubMed
42787936Circulating tumor DNA tumor fraction as a biomarker in refractory metastatic colorectal cancer: findings from the CAVE-2 GOIM trial.J Liq Biopsy2026https://conductscience.org/library/papers/42787936PubMed
42769118Cancer in a Drop: Liquid biopsy insights from AACR 2026.J Liq Biopsy2026https://conductscience.org/library/papers/42769118PubMed
42639369Liquid biopsies for detection, characterization, and interception of therapy resistance in thoracic malignancies.Front Oncol2026https://conductscience.org/library/papers/42639369PubMed
42539880Targeting tumor transition windows.Explor Target Antitumor Ther2026https://conductscience.org/library/papers/42539880PubMed
42395173Longitudinal methylated ctDNA increases predict immunotherapy progression across solid tumors.J Liq Biopsy2026https://conductscience.org/library/papers/42395173PubMed
42243127Methylation-based ctDNA monitoring in metastatic breast cancer during CDK4/6 inhibitor therapy.Nat Commun2026https://conductscience.org/library/papers/42243127PubMed
42236890Longitudinal evaluation of serial ctDNA kinetics using joint modeling in patients with metastatic breast cancer.NPJ Precis Oncol2026https://conductscience.org/library/papers/42236890PubMed
42126023From Theory to Practice: Which Biomarkers Are Ready for Predicting Response in Advanced HCC?Liver Int2026https://conductscience.org/library/papers/42126023PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41277909

GET https://conductscience.org/api/papers/v1/41277909/references?page=2